Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2020 Nov;43(11):2785-2795.
doi: 10.2337/dc20-1231. Epub 2020 Sep 10.

Comparative Effectiveness of the Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin Versus Other Antihyperglycemics on Risk of Major Adverse Kidney Events

Affiliations
Comparative Study

Comparative Effectiveness of the Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin Versus Other Antihyperglycemics on Risk of Major Adverse Kidney Events

Yan Xie et al. Diabetes Care. 2020 Nov.

Abstract

Objective: To examine the comparative effectiveness of the sodium-glucose cotransporter 2 inhibitor (SGLT2i) empagliflozin and other non-SGLT2i antihyperglycemics on the risk of major adverse kidney events (MAKE) of estimated glomerular filtration rate (eGFR) decline >50%, end-stage kidney disease, or all-cause mortality.

Research design and methods: In a cohort study of 379,033 new users of empagliflozin or other non-SGLT2i antihyperglycemics, predefined variables and covariates identified by a high-dimensional variable selection algorithm were used to build propensity scores. Weighted survival analyses were then applied to estimate the risk of MAKE.

Results: Compared with other antihyperglycemics, empagliflozin use was associated with 0.99 (95% CI 0.51, 1.55) mL/min/1.73 m2 less annual reduction in eGFR, 0.25 (95% CI 0.16, 0.33) kg/m2 more annual decrease in BMI, and reduced risk of MAKE (hazard ratio [HR] 0.68 [95% CI 0.64, 0.73]). Empagliflozin use was associated with reduced risk of MAKE in eGFR ≥90, ≥60 to <90, ≥45 to <60, and ≥30 to <45 mL/min/1.73 m2 (HR 0.70 [95% CI 0.60, 0.82], 0.66 [0.60, 0.73], 0.78 [0.69, 0.89]), and 0.71 [0.55, 0.92], respectively), in participants without albuminuria, with microalbuminuria and macroalbuminuria (HR 0.65 [95% CI 0.57, 0.75], 0.72 [0.66. 0.79], and 0.74 [0.62, 0.88], respectively), and in participants with and without cardiovascular disease (HR 0.67 [95% CI 0.61, 0.74] and 0.76 [0.69, 0.83], respectively). The association was evident in per-protocol analyses, which required continuation of the assigned antihyperglycemic medication (empagliflozin or other antihyperglycemics) during follow-up (HR 0.64 [95% CI 0.60, 0.70]), and in analyses requiring concurrent use of metformin in at least the first 90 days of follow-up (HR 0.63 [0.57-0.69]).

Conclusions: Among people with type 2 diabetes, empagliflozin use was associated with eGFR preservation, a greater decline in BMI, and a reduced risk of MAKE compared with other non-SGLT2i antihyperglycemics.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Survival probability for MAKE of eGFR decline >50%, ESKD, or all-cause mortality in the empagliflozin group (blue) and the control group of other non-SGLT2i antihyperglycemics (red) in the weighted cohort.
Figure 2
Figure 2
A: eGFR trajectory during follow-up. Estimated eGFR values and 95% CIs at 90 days and at 1, 2, and 3 years were plotted for the empagliflozin group (blue) and the control group of other non-SGLT2i antihyperglycemics (red). eGFR change associated with empagliflozin at each time point represents the difference between the two trajectories where the control group served as the reference. B: BMI trajectory during follow-up. Estimated BMI values and 95% CIs at 90 days and at 1, 2, and 3 years were plotted for the empagliflozin group (blue) and the control group of other non-SGLT2i antihyperglycemics (red). BMI change associated with empagliflozin at each time point represents the difference between the two trajectories where the control group served as the reference.
Figure 3
Figure 3
A: HRs and event rate differences for the MAKE of eGFR decline >50%, ESKD, or all-cause mortality in the overall cohort and in subgroups. B: HRs and event rate differences for individual components of the MAKE of eGFR decline >50%, ESKD, or all-cause mortality. Albuminuria status defined as no albuminuria (albumin-to-creatinine ratio ≤30 mg/g), microalbuminuria (>30 to ≤300 mg/g), and macroalbuminuria (>300 mg/g).

References

    1. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017 [published correction appears in Lancet 2019;393:e44]. Lancet 2018;392:1789–1858 - PMC - PubMed
    1. Bowe B, Xie Y, Li T, et al. . Changes in the us burden of chronic kidney disease from 2002 to 2016: an analysis of the global burden of disease study. JAMA Netw Open 2018;1:e184412. - PMC - PubMed
    1. Xie Y, Bowe B, Mokdad AH, et al. . Analysis of the Global Burden of Disease study highlights the global, regional, and national trends of chronic kidney disease epidemiology from 1990 to 2016. Kidney Int 2018;94:567–581 - PubMed
    1. GBD 2017 DALYs and HALE Collaborators Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018;392:1859–1922 - PMC - PubMed
    1. Foreman KJ, Marquez N, Dolgert A, et al. . Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016-40 for 195 countries and territories. Lancet 2018;392:2052–2090 - PMC - PubMed

Publication types

MeSH terms